Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Clin Oncol. May 24, 2024; 15(5): 614-634
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.614
Table 1 Baseline patient clinicopathological and treatment information
Clinical and pathological data
Patient groups
Significance level (P value)
Main cohort (n = 180)
Training cohort (n = 62)
n
%
n
%
Age (yr)
    < 606033.32032.30.897
    60-699854.53353.2
    ≥ 702212.2914.5
Tumor location
    Central11966.13861.30.493
    Peripheral6133.92438.7
Comorbidity
    Absence2212.2812.30.888
    Presence15887.85487.7
Histology
    KSCC5631.12133.90.687
    NKSCC12468.94166.1
Tumor grade
    G15731.72337.10.325
    G28848.93251.6
    G33519.4711.3
T stage
    T1a95.0812.90.039a
    T1b158.369.7
    T2a8245.63454.8
    T2b179.458.1
    T35731.7914.5
N stage
    N04826.72235.50.411
    N18848.92641.9
    N24424.41422.6
Stage
    I3016.72032.30.03a
    II7340.62232.4
    III7742.82032.3
Type of surgery
    Lobectomy8446.74064.40.001a
    Bilobectomy63.358.1
    Pneumonectomy8647.81321.0
    Segmentectomy42.246.5
Adjuvant therapy
    Absent5128.32743.50.002a
    Chemotherapy6837.81016.1
    Radiation therapy3821.12133.9
    Chemo- and radiotherapy2312.846.5
Table 2 Correlations between different types of tumor microvessels and characteristics of the parenchymal and stromal components of lung squamous cell carcinoma

Fragmentation in the tumor solid component
The presence of LFFCT in the tumor stroma
Retraction clefts
Tumor spread in the AASs
Gamma
P value
Gamma
P value
Gamma
P value
Gamma
P value
MVD0.2400.240.0340.840.0420.79-0.5370.002a
DCs0.0640.660.0140.900.2110.06-0.2510.04a
ADCs0.5550.0006a-0.5370.0005a0.1150.450.2480.15
SPELs0.0710.650.1240.430.5170.0006a0.4350.007a
DCs with weak expression of CD340.2970.140.9430.0000a0.1930.21-0.2100.22
Contact-type DCs0.3440.03a0.5020.001a0.6660.0000a-0.0770.66
The capillaries in the tumor solid component0.0400.820.0090.960.2310.16-0.0690.72
LVs in lymphoid and polymorphic cell infiltrates-0.5380.001a0.0540.750.2840.070.3020.08
Table 3 Univariate and multifactorial logistic regression analysis of risk factors for regional lymph node metastases in patients with lung squamous cell carcinoma
Characteristic
Univariate analysis, OR (95%CI)
P value
Multivariate analysis, OR (95%CI)
P value
Age
    < 601-
    60-691.48 (0.71-3.07)0.291
    ≥ 700.75 (0.27-2.10)0.584
Tumor location
    Peripheral1-1-
    Central4.77 (2.36-9.63)0.0000a7.80 (3.33-18.26)0.0000a
Histology
    KSCC1-
    NKSCC0.77 (0.37-1.60)0.482
Tumor grade
    G11-
    G21.07 (0.50-2.29)0.858
    G30.78 (0.31-1.97)0.597
T stage
    T1a1-1-
    T1b5.50 (0.91-33.18)0.0634.93 (0.76-31.78)0.093
    T2a6.20 (1.42-27.09)0.015a2.82 (0.59-13.53)0.195
    T2b9.33 (1.45-60.21)0.019a5.27 (0.75-37.28)0.096
    T35.60 (1.24-25.25)0.026a1.66 (0.31-8.80)0.551
DCs with weak expression of CD34
    Absence1-
    Presence1.10 (0.56-2.15)0.783
DCs of "contact type"
    Presence1-
    Absence1.67 (0.86-3.25)0.13
The capillaries in the tumor solid component
    Absence1-1-
    Presence2.89 (1.33-6.28)0.008a2.72 (1.14-6.48)0.023a
LFFCT in the tumor stroma
    Absence1-
    Presence0.70 (0.32-1.55)0.383
Fragmentation in the tumor solid component
    Absence1-1-
    Presence2.55 (1.28-5.06)0.008a3.03 (1.33-6.94)0.009a
Retraction clefts
    Absence1-1-
    Presence2.62 (1.33-5.16)0.005a3.52 (1.56-7.96)0.003a
Tumor spread through the AAS
    Absence1-
    Presence0.72 (0.37-1.42)0.342
Table 4 Univariate and multivariate analyses for the predictors of disease recurrence in patients with lung squamous cell carcinoma
Characteristic
Univariate analysis, OR (95%CI)
P value
Multivariate analysis, OR (95%CI)
P value
Age
    < 601-
    60-691.87 (0.97-3.58)0.06
    ≥ 702.45 (0.89-6.72)0.082
Tumor location
    Peripheral1-1-
    Central1.86 (0.99-3.47)0.052a1.040.92
Histology
    KSCC1-
    NKSCC1.79 (0.94-3.38)0.075
Tumor grade
    G11-1-
    G21.51 (0.76-2.95)0.2321.36 (0.59-3.01)0.466
    G33.44 (1.39-8.48)0.007a4.24 (1.37-13.14)0.001a
T stage
    T1a1-
    T1b7.00 (1.04-46.95)0.045a
    T2a4.26 (0.83-21.74)0.082
    T2b5.00 (0.79-31.62)0.087
    T33.38 (0.65-17.69)0.149
N stage
    N01-1-
    N12.00 (0.97-4.11)0.0591.89 (0.81-4.39)0.137
    N23.22 (1.37-7.57)0.007a3.43 (1.26-9.34)0.016a
Stage
    I1-1-
    II2.17 (0.89-5.27)0.0881.87 (0.45-7.69)0.385
    III3.13 (1.29-7.60)0.012a3.44 (0.50-23.49)0.207
Adjuvant therapy
    Radiation therapy1-1-
    Chemo- and radiotherapy1.41 (0.50-3.97)0.5130.57 (0.16-1.98)0.376
    Chemotherapy3.020.0082.07 (0.78-5.53)0.146
DCs with weak expression of CD34
    Absence1-1-
    Presence4.26 (2.25-8.05)0.0000a1.18 (0.43-3.23)0.749
Contact-type DCs
    Absence1-
    Presence0.97 (0.54-1.75)0.934
The capillaries in the tumor solid component
    Absence1-1-
    Presence2.32 (1.24-4.35)0.008a1.20 (0.56-2.59)0.638
LFFCT in the tumor stroma
    Absence1-1-
    Presence6.24 (2.85-13.67)0.0000a7.34 (3.03-17.76)0.0000a
Fragmentation of the tumor solid component
    Absence1-1-
    Presence3.03 (1.58-5.82)0.0009a5.23 (2.27-12.07)0.0001a
Retraction clefts
    Absence1-
    Presence0.71 (0.38-1.29)0.262
Tumor spread through the AASs
    Presence1-1-
    Absence2.06 (1.13-3.76)0.019a3.37 (1.22-5.66)0.0083a